Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project--part 2). (Q34415439)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project--part 2). |
scientific article |
Statements
1 reference
Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project--part 2). (English)
1 reference
Jacques Cadranel
1 reference
Michele Faller
1 reference
Gérard Zalcman
1 reference
Virginie Westeel
1 reference
Elisabeth Longchampt
1 reference
Catherine Daniel
1 reference
Bruno Chetaille
1 reference
Stephane Michiels
1 reference
Pascal Foucher
1 reference
Thierry Urban
1 reference
Ludovic Lacroix
1 reference
Virginie Poulot
1 reference
Elisabeth Quoix
1 reference
Martine Antoine
1 reference
Guillaume Danton
1 reference
Franck Morin
1 reference
1 October 2012
1 reference
1 reference
Identifiers
1 reference